The most promising miRNA that could be used as therapeutic target in CLL is miR-34a, an onco-suppressor deregulated in del17p- and TP53-mutated patients and inversely correlated with prognosis and fludarabine refractoriness [38,39]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.